The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea

키워드

참고문헌 (27)

1. Labrie F, "Gonadotropin-releasing hormone agonists in the treatment of prostate cancer", Endocr Rev, 26, pp.361~379 (2005)
2. Sanghani MV, "Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen deprivationtherapy in patients with prostate cancer", Urology, 62(3 Suppl), pp.487~491 (2003)
3. McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
4. 조강준, "Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia", International Neurourology Journal, 15(3), pp.152~157 (2011), 대한배뇨장애요실금학회
5. Hamilton W, "Symptomatic diagnosis of prostate cancer in primary care: a structured review", Br J Gen Pract, 54, pp.617~621 (2004)
6. Guess HA, "Benign prostatic hyperplasia and prostate cancer", Epidemiol Rev, 23, pp.152~158 (2001)
7. 김태헌, "The Prevalence of Lower Urinary Tract Symptoms in Korean Men Aged 40 Years or Older: A Population-Based Survey", International Neurourology Journal, 18(3), pp.126~132 (2014), 대한배뇨장애요실금학회
8. 최훈, "Analysis of Initial Baseline Clinical Parameters and Treatment Strategy Associated with Medication Failure in the Treatment of Benign Prostatic Hyperplasia in Korea", International Neurourology Journal, 14(4), pp.261~266 (2010), 대한배뇨장애요실금학회
9. Tolis G, "Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists", Proc Natl Acad Sci U S A, 79, pp.1658~1662 (1982)
10. Gioeli DG, "The promise of novel androgen receptor antagonists", Cell Cycle, 9, pp.440~441 (2010)
11. Lehrer S, "Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer", Urol Oncol, 7, pp.73~76 (2002)
12. Barry MJ, "Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?", J Urol, 154, pp.1770~1774 (1995)
13. Ebara S, "The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer", Acta Med Okayama, 61, pp.335~340 (2007)
14. Frazier A, "Prostate volume reduction induced by neoadjuvant androgen ablation in preparation for permanent radioactive seed implantation", Radiother Oncol, 55(Suppl 1), pp.77~78 (2000)
15. Axcrona K, "Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide", BJU Int, 110, pp.1721~1728 (2012)
16. Gleave ME, "Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects", J Urol, 166, pp.500~506 (2001)
17. Langenhuijsen JF, "Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy", Urol Oncol, 29, pp.52~57 (2011)
18. Sanghani MV, "Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer", Urology, 62, pp.487~491 (2003)
19. Kucway R, "Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy", J Urol, 167, pp.2443~2447 (2002)
20. Whittington R, "The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate", Int J Radiat Oncol Biol Phys, 44, pp.1107~1110 (1999)
21. Wilson S, "Downsizing and prostate cancer", Rev Urol, 6(Suppl 7), pp.S19~S24 (2004)
22. Klarskov LL, "Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study", Scand J Urol Nephrol, 46, pp.37~43 (2012)
23. Anderson J, "Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)", Urol Int, 90, pp.321~328 (2013)
24. Russo A, "Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats", Eur Urol, 59, pp.868~874 (2011)
25. Bahk JY, "Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation", Urol Int, 80, pp.431~438 (2008)
26. Rick FG, "LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia", Prostate, 71, pp.736~747 (2011)
27. Siejka A, "Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix", BJU Int, 106, pp.1382~1388 (2010)

관련 논문AI추천